Research: Can Thin Needles Cure Women's "Unemployment Problem"? Probability of Dating New People Also Surges

Harvard economist Rebecca Diamond's latest research found that women using GLP-1 weight-loss injections had a 27 percentage point higher employment rate among the unemployed compared to non-users, and single individuals had a 29 percentage point higher chance of forming a partner relationship. But the real issue doesn't seem to be the drug's efficacy.
(Background: AI recruitment tools exposed for racial discrimination! Stanford research shows systematic inequality for Black and Asian populations)
(Context: 8 must-have items for crypto elites, how many do you have?)

Table of Contents

Toggle

• The Control Group: Injections, No Life Changes
• A Gender Tax
• Obesity Itself Is a Wealth Filter

Key Takeaways

• Harvard economist Rebecca Diamond's study found that unemployed women using GLP-1 weight-loss injections had a 27 percentage point higher employment rate after 18 months, and single women had a 29 percentage point higher chance of forming a partner relationship.
• The effect only appears in first-encounter situations; for employed women, salaries and working hours did not increase, and existing partner relationships did not change, indicating this is about first-impression appearance discrimination, not health or productivity.
• About 40% of users in the study sample paid out-of-pocket, with a median monthly cost around $275. Users are concentrated in high-income groups, suggesting obesity may become tied to low income, creating a new class divide.

The most important part of this study is not the headline content.

Most headlines report that "weight-loss injections help women find jobs and partners," which isn't wrong. Harvard economist Rebecca Diamond's June study indeed shows that unemployed women who took GLP-1 weight-loss drugs had a 27 percentage point higher employment rate after 18 months compared to those who didn't, and single women had a 29 percentage point higher chance of forming a partner relationship.

These numbers are astonishing and easy to understand: women's evaluations are tied to body shape, whether from others or themselves.

But in the same study, another control group's numbers didn't budge at all. Women who already had jobs didn't see salary increases, reduced working hours, or promotions after taking the injections. Existing partner relationships did not become closer.

This drug, supposedly life-changing, has almost no effect on those "already inside." It only works when strangers are sizing you up. So the statistical results of this drug's effect become a story about gender bias and money.

The Control Group: Injections, No Life Changes

Rebecca Diamond's own interpretation is quite restrained. She says these results are consistent with the hypothesis that part of the "female obesity penalty" occurs during the formation of new pairings, not just through health or existing job performance.

Her point is that this social penalty tied to women is not a penalty on their abilities, but rather a penalty incurred at the first glance. Colleagues and partners know your work ability and personality, so existing bosses and partners don't give new evaluations just because a woman becomes thinner. But someone sizing you up for the first time has only a few seconds, and the only information they can access is the visual impression of your body.

Weight-loss injections sell the ability to pass that initial evaluation in those few seconds.

A Gender Tax

To understand why this initial screening exists, we must first admit something many are reluctant to clarify: this penalty almost exclusively taxes women.

This is not a new discovery. Economist John Cawley quantified the so-called "obesity wage penalty" years ago. He estimated that overweight white women earn about 4.5% less than normal-weight women, while obese women earn about 20% less.

When the same standard is applied to men, the results are mixed. Sometimes the penalty is very small, and sometimes weight and salary even show a positive correlation. Some believe overweight men appear more "authoritative."

Economist Daniel Hamermesh, in his book Beauty Pays, put it bluntly: the workplace gives a bonus to "good-looking" people. The obesity penalty is just the flip side of this beauty premium. Weight loss has a price tag in the labor market, and this evaluation is particularly harsh for women.

There's an even more striking detail hidden in Diamond's data: with the same weight-loss injections, men who already had partners were more likely to leave their partners after losing weight.

Obesity Itself Is a Wealth Filter

The invention of weight-loss injections has worsened the wealth-filtering effect of obesity.

Diamond's data shows that about 40% of users in the study sample paid out-of-pocket, with a median monthly cost of around $275. Users are overwhelmingly in the highest household income brackets, while those who cannot access the drug are in the lowest income brackets.

So the female obesity penalty does not disappear because of the drug; it is simply filtered by wealth. Those who can afford it buy the right to a good first impression; those who can't continue to be penalized by first impressions. "Fat" is settling downward in the class structure.

When discrimination can be treated with a prescription drug, society stops trying to solve it, because the pressure from the issue has been absorbed by the pharmaceutical industry.

So the next time you hear someone say weight-loss injections are "changing women's destinies," we know it's not all women's destinies, nor all men's.

FAQ

Can weight-loss injections really help women find jobs and partners?

According to Rebecca Diamond's study, unemployed women using GLP-1 injections had a 27 percentage point higher employment rate after 18 months, and single women had a 29 percentage point higher chance of forming a partner relationship. However, the effect is concentrated on first interviews and first dates; employed women's salaries did not increase, indicating that what changed was first impressions, not ability.

Why might weight-loss injections widen the wealth gap?

About 40% of users in the study sample paid out-of-pocket, with a median monthly cost of around $275. Users are mostly from high-income groups. If weight-loss drugs are long-term accessed only by the wealthy, obesity may become increasingly tied to low income, causing appearance penalties to be filtered by wealth, creating a new class divide and stigma.